• 1. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 4. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 5. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids

Introduction to Methyl 2-Ethenyl-3-Fluoropyridine-4-Carboxylate (CAS No. 1379375-19-5)

Methyl 2-ethenyl-3-fluoropyridine-4-carboxylate, identified by its CAS number 1379375-19-5, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the pyridine family, a heterocyclic aromatic compound characterized by a nitrogen atom incorporated into its six-membered ring structure. The presence of both ethenyl and fluorine substituents in its molecular framework imparts unique chemical properties, making it a valuable intermediate in the synthesis of various bioactive molecules.

The molecular structure of methyl 2-ethenyl-3-fluoropyridine-4-carboxylate consists of a pyridine core substituted with an ethenyl group at the 2-position and a fluorine atom at the 3-position, with a carboxylate ester group at the 4-position. This specific arrangement of functional groups enhances its reactivity and potential applications in drug discovery and development. The fluorine atom, in particular, is known for its ability to modulate metabolic stability and binding affinity, which are critical factors in pharmaceutical design.

In recent years, there has been a surge in research focused on fluorinated pyridines due to their broad spectrum of biological activities. These compounds have been explored for their potential in developing treatments for various diseases, including cancer, infectious diseases, and neurological disorders. The ethenyl group in methyl 2-ethenyl-3-fluoropyridine-4-carboxylate also contributes to its versatility, allowing for further functionalization through cross-coupling reactions such as Suzuki-Miyaura and Heck couplings. These reactions are pivotal in constructing complex molecular architectures that mimic natural products and bioactive peptides.

One of the most compelling aspects of methyl 2-ethenyl-3-fluoropyridine-4-carboxylate is its role as a building block in the synthesis of small-molecule inhibitors. For instance, studies have demonstrated its utility in creating kinase inhibitors, which are essential in targeting aberrant signaling pathways involved in cancer progression. The fluorine atom's electronic properties can fine-tune the binding interactions between the inhibitor and its target protein, thereby improving efficacy and selectivity. Additionally, the carboxylate ester group provides a handle for further derivatization, enabling the creation of prodrugs or conjugates that enhance bioavailability and tissue distribution.

The pharmaceutical industry has increasingly recognized the importance of heterocyclic compounds like methyl 2-ethenyl-3-fluoropyridine-4-carboxylate due to their diverse pharmacological profiles. Researchers have leveraged computational modeling and high-throughput screening to identify novel derivatives with enhanced therapeutic potential. The compound's ability to engage multiple binding sites on biological targets has opened up new avenues for developing multitarget drugs, which are designed to address complex diseases more effectively than single-target agents.

Moreover, the synthesis of methyl 2-ethenyl-3-fluoropyridine-4-carboxylate has been optimized for scalability and efficiency, making it accessible for industrial applications. Advanced synthetic methodologies, including flow chemistry and microwave-assisted reactions, have been employed to improve yield and reduce environmental impact. These advancements align with the growing emphasis on green chemistry principles within the pharmaceutical sector.

Recent clinical trials have highlighted the promise of fluorinated pyridines as pharmacophores in drug development. For example, compounds derived from methyl 2-ethenyl-3-fluoropyridine-4-carboxylate have shown promising results in preclinical studies targeting oncogenic pathways. The ability of these compounds to inhibit key enzymes involved in tumor growth and survival underscores their therapeutic potential. As research progresses, it is anticipated that additional derivatives will be developed and tested, further solidifying their role in next-generation therapeutics.

The versatility of methyl 2-ethenyl-3-fluoropyridine-4-carboxylate extends beyond its applications in drug discovery. It has also been explored as a key intermediate in materials science, particularly in the development of organic electronic materials such as semiconductors and light-emitting diodes (LEDs). The unique electronic properties conferred by the fluorine substituent make it an attractive candidate for designing advanced functional materials with applications ranging from flexible electronics to photovoltaic devices.

In conclusion, methyl 2-ethenyl-3-fluoropyridine-4-carboxylate (CAS No. 1379375-19-5) is a multifaceted compound with significant implications across multiple scientific disciplines. Its role as a synthetic intermediate in pharmaceutical chemistry has led to numerous innovative applications, particularly in developing targeted therapeutics for complex diseases. As research continues to uncover new possibilities for this compound and its derivatives, its importance is expected to grow even further.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)